Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial

PURPOSE: To evaluate efficacy and safety of veliparib combined with carboplatin/paclitaxel in patients with advanced human epidermal growth factor receptor 2 (HER2)-negative, germline BRCA (gBRCA)-associated breast cancer defined by hormone receptor (HR) and gBRCA1/2 mutation status. PATIENTS AND ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayoub, Jean-Pierre, Wildiers, Hans, Friedlander, Michael, Arun, Banu K., Han, Hyo S., Puhalla, Shannon, Shparyk, Yaroslav, Jakobsen, Erik H., Wu, Meijing, Bach, Bruce A., Feng, Dai, Ratajczak, Christine K., Maag, David, Diéras, Véronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669119/
https://www.ncbi.nlm.nih.gov/pubmed/34917174
http://dx.doi.org/10.1177/17588359211059601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669119/
https://www.ncbi.nlm.nih.gov/pubmed/34917174
http://dx.doi.org/10.1177/17588359211059601

Ejemplares similares